• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MedImmune

MedImmune

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. AstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

    AstraZeneca Delivers New Data on Expanding Portfolio of Cancer Medicines at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

  2. Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and Markets

    Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and Markets

  3. Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients

    Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients

  4. Medidata’s Julie Iskow Named a “Luminary” by the Healthcare Businesswomen’s Association

    Medidata’s Julie Iskow Named a “Luminary” by the Healthcare Businesswomen’s Association

  5. Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Pipeline Report H1 2017 - Review of 14 Companies & Drug Profiles Including Celgene, Merck & Pfizer - Research and Markets

    Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics Pipeline Report H1 2017 - Review of 14 Companies & Drug Profiles Including Celgene, Merck & Pfizer - Research and Markets

  6. AstraZeneca’s IMFINZI™ (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer

    AstraZeneca’s IMFINZI™ (durvalumab) Receives US FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer

  7. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  8. Biotech Investing for the Long Haul

    Three ways to separate long-term winners from stocks that fizzle.

  9. Morningstar Indexes: Weekly Market Report

    Week ending April 27: Quarterly earnings continue to boost market's spirits. 

  10. Services Super Sector: Major Themes

    Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...

©2017 Morningstar Advisor. All right reserved.